GSK Medication: Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives:

Size: px
Start display at page:

Download "GSK Medication: Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives:"

Transcription

1 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country. GSK Medication: Cervarix Study No.: (HPV-015) Title: A phase III, double-blind, randomized, controlled study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals HPV-16/18 L1 VLP AS04 vaccine administered intramuscularly according to a three-dose schedule (0, 1, 6 month) in healthy adult female subjects aged 26 years and above. Cervarix - HPV-16/18 L1 VLP AS04 (HPV): GlaxoSmithKline (GSK) Biologicals candidate human papillomavirus (HPV) vaccine containing HPV 16/18 virus-like particles (VLPs). Rationale: The aim of the study was to evaluate the safety, immunogenicity and efficacy of the HPV vaccine in women aged 26 years and above. An interim analysis would be performed when at least 40 cases of persistent infection with HPV-16/18 and/or CIN1+ associated with HPV-16/18 were detected in the ATP cohort for efficacy, in HPV DNA negative and seronegative subjects at baseline or when all subjects had completed the Month 48 visit. A final analysis would be performed if (1) at least 405 cases of CIN1+ irrespective of HPV type found in the lesion, irrespective of HPV DNA and serological status at baseline in the TVC are reached before all subjects have completed the Month 84 visit, or (2) at study conclusion (Month 84). Since Study conclusion was reached, the final analysis was performed. Phase: III Study Period: - 16 February 2006 to 10 December 2010 (Month 48) - 29 January 2014 (Month 84) Study Design: Double-blind, multi-centre, randomized (1:1), controlled study with 2 parallel groups. Blinding will be maintained and follow-up will be continued for all subjects until Month 84 (end of the study). Centres: 76 study centres divided in 4 regions: Asia Pacific [Australia (2), Philippines (3), Singapore (3) and Thailand (2)], Europe [Portugal (5), Russia (6), Netherlands (3) and United Kingdom (6)], Latin America [Mexico (2) and Peru (1)] and North America [United States of America (36) and Canada (7)]. Indication: Active immunisation of females from 9 years of age onwards for the prevention of cervical cancer by protecting against incident and persistent infections, cytological abnormalities including atypical squamous cells of undetermined significance (ASC-US), cervical intraepithelial neoplasia (CIN) and pre-cancerous lesions (CIN 2/3) caused by oncogenic human papillomaviruses (HPV). Treatment: The study groups were as follows: HPV Group received the HPV vaccine Control Group received the control Aluminium Hydroxide [Al(OH)3] Both study groups received 3 doses of either the HPV vaccine or the control by intramuscular injection into the deltoid region of the non-dominant arm according to a 0, 1, 6 month schedule. Note: enrolment was stratified by (1) age, with the majority of subjects in age strata years and years (about 45% each) and about 10% in the age stratum 46+ years, and (2) previous HPV history (in each age stratum, the number of women with a history of HPV infection/treatment was limited to approximately 15%). Objectives: To demonstrate efficacy of the candidate vaccine in the prevention of (1) persistent infection (6-month definition) with HPV-16 or HPV-18 (by polymerase chain reaction [PCR]) and/or (2) histopathologically confirmed CIN1*+ associated with HPV-16 or HPV-18 cervical infection detected within the lesional component of the cervical tissue specimen (by PCR), overall and stratified according to initial (Month 0) HPV-16 or HPV-18 serostatus (by enzymelinked immunosorbent assay [ELISA]). If efficacy was demonstrated, the following objective would be assessed sequentially: To demonstrate efficacy of the candidate vaccine compared with control in the prevention of (1) persistent infection (6-month definition) with HPV-16 or HPV-18 (by PCR) and/or (2) histopathologically-confirmed CIN1+ associated with HPV-16 or HPV-18 cervical infection detected using the HPV Type Assignment Algorithm (TAA), overall and stratified according to initial (Month 0) HPV-16 or HPV-18 serostatus (by ELISA). *CIN1+: Cervical intraepithelial neoplasia CIN1, CIN2, CIN3, adenocarcinoma in-situ (AIS) and invasive cervical cancer. Primary Outcome/Efficacy Variable:

2 Persistent infection (6-month definition) with HPV-16 or HPV-18 (by PCR) and/or histopathologically confirmed CIN1+ associated with HPV-16 or HPV-18 cervical infection detected within the lesional component of the cervical tissue specimen (by PCR) (combined endpoint), overall and stratified according to initial (Month 0) HPV-16 or HPV- 18 serostatus (by ELISA). Persistent infection (6-month definition) with HPV-16 or HPV-18 (by PCR) and/or histopathologically-confirmed CIN1+ associated with HPV-16 or HPV-18 cervical infection detected using the HPV TAA, overall and stratified according to initial (Month 0) HPV-16 or HPV-18 serostatus (by ELISA). Persistent cervical HPV infection (6-month definition) was defined as detection of the same HPV type(s) (by PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. Note: Unless otherwise specified these primary outcomes were assessed post-dose 3 in adult women who were negative for HPV DNA (by PCR) at Months 0 and 6 for the corresponding HPV type. Secondary Outcome/Efficacy Variable(s): Virological Persistent infection (6-month definition) with HPV-16 or HPV-18 (by PCR), overall and stratified according to initial (Month 0) HPV-16 or HPV-18 serostatus (by ELISA). Persistent infection (12-month definition) with HPV-16 or HPV-18 (by PCR), overall and stratified according to initial (Month 0) HPV-16 or HPV-18 serostatus (by ELISA). Persistent infection (6-month definition) with oncogenic HPV types (e.g. HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68, by PCR), individually or in combinations, in subjects HPV DNA negative for the type considered, regardless of initial serostatus. Persistent infection (12-month definition) with oncogenic HPV types (e.g. HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68, by PCR), individually or in combinations, in subjects HPV DNA negative for the type considered, regardless of initial serostatus. Persistent cervical HPV infection (12-month definition) was defined as the detection of the same HPV type(s) (by PCR) in cervical samples at all available time points over approximately a 12-month interval (evaluations are planned at approximately 6-month intervals). Histopathological Histopathologically confirmed CIN2+ associated with HPV-16 or HPV-18 cervical infection detected within the lesional component of the cervical tissue specimen (by PCR), and using the HPV TAA*, overall and stratified according to initial (Month 0) HPV-16 or HPV-18 serostatus (by ELISA). CIN2+ (cervical intraepithelial neoplasia) was defined as CIN2, CIN3, adenocarcinoma in-situ (AIS) and invasive cervical cancer. Histopathologically confirmed CIN1+ associated with HPV-16 or HPV-18 cervical infection detected within the lesional component of the cervical tissue specimen (by PCR), and using the HPV TAA*, overall and stratified according to initial (Month 0) HPV-16 or HPV-18 serostatus (by ELISA). Histopathologically-confirmed CIN1+ associated with HPV-16 and/or HPV-18 cervical infection detected within the lesional component of the cervical tissue specimen (by PCR), and using the HPV TAA*, irrespective of baseline HPV DNA and serostatus. Histopathologically-confirmed CIN1+ irrespective of HPV cervical infection and irrespective of baseline HPV DNA status. * As the vaccine efficacy was not demonstrated for the primary case definition (detection within the lesional component of the cervical tissue specimen by PCR), these analyses are not presented. Cytological Any cytological abnormality associated with HPV-16 or HPV-18 cervical infection (by PCR), overall and stratified according to initial (Month 0) HPV-16 or HPV-18 serostatus (by ELISA). Any cytological abnormality associated with oncogenic HPV types (e.g. HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68, by PCR),individually or in combinations, in subjects HPV DNA negative for the type considered, regardless of initial serostatus. Administration of colposcopy referrals and local cervical therapy (LEEP, CONE, KNIFE or LASER), irrespective of baseline HPV DNA status. Persistent infection (6-month definition) with HPV-16 or HPV-18 (by PCR) and/or histopathologically-confirmed CIN1+ associated with HPV-16 or HPV-18 cervical infection detected within the lesional component of the cervical tissue specimen (by PCR), and using the HPV TAA, irrespective of baseline HPV DNA and serostatus. Results for seropositive status were not analysed. Note: Unless otherwise specified, the secondary outcomes listed here above were assessed post-dose 3 in adult women who

3 were negative for HPV DNA (by PCR) at Months 0 and 6 for the corresponding HPV type. Immunogenicity HPV-16 and HPV-18 ELISA titres and seroconversion* at Months 7, 24, 48 and 84 (all subjects) and at Months 12, 18, 36, 60 and 72 (in the immunogenicity subset).these analyses were stratified according to initial (Month 0) HPV-16 or HPV-18 serostatus. Viral neutralization might be assessed in a selected subset of subjects. HPV-16 and HPV-18 ELISA titres and seroconversion were assessed in vaccine recipients with breakthrough HPV-16 and/or HPV-18 persistent infections and HPV-16 and/or HPV-18 associated CIN1+ lesions. These were compared with selected non-cases (vaccine recipients without persistent infection or CIN1+, matched for age, race and clinic site). Antibody titres and seroconversion for V5/J4 monoclonal antibody inhibition testing and/or viral neutralization might also be assessed on these samples. These analyses were restricted to subjects who were seronegative for the corresponding HPV type prior to vaccination **. * Seroconversion was defined as the appearance of antibodies (i.e. concentration/titre greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination. **Due to the low number of breakthrough cases, this analysis could not be performed. Safety Occurrence, intensity, relationship to vaccination and resulting school or work absenteeism (as applicable) of solicited local or solicited general symptoms within 7 days (Days 0-6) after each vaccination. Occurrence, intensity, relationship to vaccination and resulting school or work absenteeism (as applicable) of unsolicited symptoms within 30 days (Days 0-29) after each vaccination. Occurrence and relationship to vaccination of serious adverse events (SAEs) throughout the entire study period (up to Month 48). Occurrence of any SAE related to vaccination, other GSK medication or study procedures, any fatal SAE and any AE/SAE leading to premature discontinuation of the study throughout the entire study period up to Month 84. Occurrence of new onset chronic diseases (NOCDs) (e.g. autoimmune disorders, asthma, type I diabetes) throughout the entire study period (up to Month 48). Occurrence of new onset autoimmune diseases (NOADs)(e.g. autoimmune disorders, asthma, type I diabetes) throughout the entire study period (up to Month 48). Occurrence of medically significant conditions (MSCs) throughout the entire study period (up to Month 48) #. Occurrence of pregnancies and their outcomes throughout the entire study period (up to Month 48). # Medically significant conditions were defined as: AEs prompting emergency room or physician visits that were not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or SAEs that were not related to common diseases. Common diseases included: upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervicovaginal yeast infections, menstrual cycle abnormalities and injury. Statistical Methods: The analyses were performed on the Total Vaccinated cohort, the According To Protocol (ATP) cohort for efficacy and the ATP cohort for Immunogenicity. - The Total Vaccinated cohort included all subjects with at least one vaccine administration documented. - The ATP cohort for efficacy included all evaluable subjects (i.e. those meeting all eligibility criteria, complying with the procedures defined in the protocol, with no elimination violations) who had a normal or low-grade cytology (negative or ASC-US or LSIL) at Month 0, with no more than one cervix, who received 3 doses administered according to protocol, with no administration of vaccine forbidden and with negative pregnancy test at Month 0, 1 and 6. This cohort excluded the 15% subset of women enrolled with prior history of HPV disease/infection. - The ATP cohort for immunogenicity included all evaluable subjects (i.e. who meet all eligibility criteria, who comply with the procedures defined in the protocol, with no elimination criteria during the study) for whom data concerning any immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination. This cohort included the 15% subset of women enrolled with prior history of HPV disease/infection. Note: Five blood samples were to be collected at Months 0, 7, 24, 48 and 84 in all subjects. Additional blood samples were to be drawn in a subset of subjects from selected sites (immunogenicity subset: N 1000, at least 250 per region) at Months 12, 18, 36, 60 and 72. Analysis of Efficacy: The analysis was performed on the ATP cohort for efficacy and the Total Vaccinated cohort. The significance level for the interim analysis was calculated as Therefore a 97.7% confidence interval (CI) was calculated. Similarly, a significance level of and a 96.2% CI was calculated for the final analysis.

4 The analysis of the primary outcome and cytological and histopathological outcome variables associated with HPV-16 or HPV- 18 in the ATP cohort for efficacy was stratified according to initial (Month 0) HPV-16 or 18 serostatus (by ELISA). Vaccine efficacy for comparison of the 2 groups, HPV and Control, was calculated by 1 minus the rate ratio (ratio of the event rate in HPV group versus Control group) with its exact 97.7% CI for interim analysis and exact 96.2% CI for final analysis, using the conditional exact method and taking into account the follow-up time of subjects within each group. This was assessed in the prevention of 6-month persistent infection with HPV-16/-18 (by PCR) and/or histopathologically-confirmed C1N1+ associated with HPV-16/-18 cervical infection detected within the lesional component of the cervical tissue specimen (by PCR) (combined endpoint) or detected using the HPV TAA. Attack rates in each group (number of subjects with an event divided by the total number of subjects) were also compared using the Fisher s exact test. Vaccine efficacy was also calculated using conditional exact method and tabulated for the following variables: - Incidence rates and vaccine efficacy against persistent infection (6-month definition and 12 month definition) with HPV-16 and/or HPV-18 (by PCR) in HPV DNA negative and according to or regardless of the initial serostatus at baseline. - Incidence rates and vaccine efficacy against persistent infection (6-month definition and 12-month definition) with oncogenic HPV types individually or in combination, in HPV DNA negative subjects for the type considered, at baseline and regardless of initial status. - Incidence rates and vaccine efficacy against histopathologically confirmed CIN2+ associated with HPV-16 and/or HPV-18 cervical infection detected within the lesional component of the cervical tissue specimen (by PCR) in HPV DNA negative and seronegative subjects at baseline or regardless of the initial serostatus. - Incidence rates and vaccine efficacy against histopathologically confirmed CIN1+ associated with HPV-16 and/or HPV-18 cervical infection detected within the lesional component of the cervical tissue specimen (by PCR) or detected using the TAA in HPV DNA negative and according to or regardless of the initial serostatus at baseline. - Incidence rates and vaccine efficacy against histopathologically confirmed CIN1+ associated with HPV-16 and/or HPV-18 cervical infection detected within the lesional component of the cervical tissue specimen (by PCR) in all subjects, irrespective of their baseline HPV DNA status. - Incidence rates and vaccine efficacy against histopathologically confirmed CIN1+ irrespective of HPV DNA results in all subjects, irrespective of their baseline HPV DNA status. - Incidence rates and vaccine efficacy against cytological abnormalities (ASCUS+) associated with HPV-16 and/or HPV-18 cervical infection in HPV DNA negative and seronegative subjects at baseline or regardless of the initial serostatus. - Incidence rates and vaccine efficacy against cytological abnormalities (ASCUS+) associated with oncogenic HPV types individually or in combination, in HPV DNA negative subjects at baseline. - Incidence rates and vaccine efficacy in histopathologically confirmed reduction of local cervical therapy in all subjects, irrespective of their baseline HPV DNA status. - Incidence rates and vaccine efficacy against persistent infection (6-month definition) with HPV-16 and/or HPV-18 (by PCR) and/or CIN1+ associated with HPV-16 and/or HPV-18 cervical infection detected within the lesional component of the cervical tissue specimen (by PCR) or detected using the TAA in all subjects, irrespective of their baseline HPV DNA status and serostatus. Analysis of Immunogenicity: The analysis was performed on the ATP cohort for immunogenicity. For each group, at each time point that a blood sample result was collected (i.e. Months 0, 7, 24, 48 and 84 for all subjects, and Months 12, 18, 36, 60, 72 for the immunogenicity subset), seropositivity rate and geometric mean concentrations/titres (GMCs/GMTs) were tabulated with 95% CIs, by group and by initial HPV-16 and HPV-18 serostatus and overall. Viral neutralization was tabulated for both HPV-16 and HPV-18 antibodies by group and by initial status, up to Month 48. From Months 72 onwards, in order to increase the assay precision used to measure anti-hpv-16/-18 antibody titers, the assay cut-off value was changed from 8 EL.U/mL to 19 EL.U/mL for HPV-16 and from 7 EL.U/mL to 18 EL.U/mL for HPV-18. Analysis of safety: The analysis was performed on the Total Vaccinated cohort The percentages of subjects with at least one solicited local or general symptom and symptoms resulting in school/work absenteeism reported during the solicited follow-up period (Days 0-6) after each vaccination were tabulated with exact 95% CIs by group after each vaccine dose and across doses. The same tabulation was done for grade 3 solicited symptoms and solicited general symptoms assessed as related to vaccination by the investigator. The percentage of subjects with unsolicited adverse events (AEs) and unsolicited symptoms resulting in school/work absenteeism classified by the Medical Dictionary for Regulatory Activities (MedDRA) preferred terms, and reported within 30 days (Days 0-29) after each vaccination was tabulated by group. The percentages of grade 3 unsolicited AEs and unsolicited AEs with relationship to vaccination as assessed by the investigator were also tabulated by

5 group. The percentages of subjects with at least one report of NOCDs, NOADs and medically significant adverse events, classified by the MedDRA preferred terms and reported during the follow-up period up to Month 48 were tabulated by group. The percentage of pregnancies and their outcome up to Month 48 was tabulated by group. The percentage and relationship to vaccination of SAEs, was tabulated according to the MedDRA preferred terms, throughout the entire study period. The percentage of SAEs causally related to vaccination, other GSK medication or study procedures, any fatal SAE and any AEs/SAEs leading to premature discontinuation of the study throughout the follow-up period up to Month 84 was tabulated according to the MedDRA preferred terms. Study Population: Healthy female subjects aged at least 26 years of age at the time of first vaccination, free of obvious health problems before entering the study, and having had a negative pregnancy urine test were enrolled. Subjects had to be of non-childbearing potential, or if of childbearing potential, had to be abstinent or using an effective birth control method for 30 days prior to the first vaccination and had to agree to continue such precautions for 2 months after completion of vaccination series. Subjects had to have an intact cervix (no history of cauterization or surgical treatment involving damage to the transformation zone of the cervix) or have a cervix (if the subject had a previous history of HPV infection or an HPV treatment). In addition, written informed consent was obtained from the subject prior to any study procedure. Number of subjects (At the interim analysis Month 48) HPV Group Control Group Planned, N Randomised, N (Total Vaccinated cohort) Completed *, n (%) 2456 (85.2) 2438 (84.9) Total Number Subjects Withdrawn, n (%) 425 (14.8) 433 (15.1) Withdrawn due to Adverse Events, n (%) 28 (1.0) 13 (0.5) Withdrawn due to Lack of Efficacy, n (%) Not applicable Not applicable Withdrawn for other reasons, n (%) 397 (13.8) 420 (14.6) Demographics HPV Group Control Group N (Total Vaccinated cohort) Females:Males 2881:0 2871:0 Mean Age, years (SD) 37.0 (7.24) 37.0 (7.32) White/Caucasian, n (%) 1202 (41.7) 1215 (42.3) * Some subjects completed the study at Month 36 since they did not want to participate to the one-year extension up to Month 48. The number of subjects who participated up to Month 48 in the HPV Group = 2305 (80.0%) and in the Control Group = 2281 (79.4%). Number of subjects (At final analysis Month 84) HPV Group Control Group Planned, N Randomised, N (Total Vaccinated cohort) Consented for Extension at Month 84* Completed for Month 84, n (%) 1904 (66.2) 1881 (65.5) Total Number Subjects Withdrawn, n (%) 242 (11.3) 235 (11.1) Withdrawn due to Adverse Events, n (%) 4 (0.2) 2 (0.1) Withdrawn due to Lack of Efficacy, n (%) Not applicable Not applicable Withdrawn for other reasons, n (%) 238 (11.1) 233 (11.0) Demographics HPV Group Control Group N (Total Vaccinated cohort) Females:Males 2877:0 2870:0 Mean Age, years (SD) 37.0 (7.2) 37.0 (7.3) Median Age, years (minimum, maximum) 37 (24, 72) 37 (26, 68) White/Caucasian, n (%) 1202 (41.8) 1215 (42.3) Hispanic, n (%) 801 (27.8) 802 (27.9) East & South East Asian, n (%) 629 (21.9) 620 (21.6) * Some subjects completed the study at Month 48 since they did not want to participate to the extension up to Month 84. Primary Efficacy Results: Incidence rates and vaccine efficacy against persistent infection (6-month definition) with HPV-16 and/or HPV-18 (by PCR) and/or CIN1+ associated with HPV-16 and/or HPV-18 cervical infection (combined endpoint) in HPV DNA negative and seronegative subjects at baseline, using conditional exact method, at the Month 48 timepoint (ATP cohort for efficacy)

6 P-value (Per100) HPV-16/18 HPV < Control HPV-16 HPV < Control HPV-18 HPV Control For single type: Subjects DNA negative at Month 0 and Month 6 and seronegative at Month 0 for the corresponding HPV type For combined types: Subjects DNA negative at Month 0 and Month 6 and seronegative at Month 0 for at least one HPV type (subjects were in the analysis of at least one single type) Subjects with an event are DNA negative at Month 0 and Month 6 and seronegative at Month 0 for the corresponding HPV type Follow-up period started at day after Dose 3 LL,UL=97.7% Lower and Upper confidence limits P-value=Two-sided Fisher Exact test Primary Efficacy Results: Incidence rates and vaccine efficacy against persistent infection (6-month definition) with HPV-16 and/or HPV-18 (by PCR) and/or CIN1+ associated with HPV-16 and/or HPV-18 cervical infection (combined endpoint) in HPV DNA negative and seropositive subjects at baseline, using conditional exact method, at the Month 48 time point (ATP cohort for efficacy) P-value (Per100) HPV-16/18 HPV Control HPV-16 HPV Control HPV-18 HPV Control For single type: Subjects DNA negative at Month 0 and Month 6 and seropositive at Month 0 for the corresponding HPV type For combined types: Subjects DNA negative at Month 0 and Month 6 and seropositive at Month 0 for at least one HPV type (subjects were in the analysis of at least one single type) Subjects with an event are DNA negative at Month 0 and Month 6 and seropositive at Month 0 for the corresponding HPV type Follow-up period started at day after Dose 3 LL,UL=97.7% Lower and Upper confidence limits P-value=Two-sided Fisher Exact test Primary Efficacy Results: Incidence rates and vaccine efficacy against persistent infection (6-month definition) with HPV-16 and/or HPV-18 (by PCR) and/or CIN1+ associated with HPV-16 and/or HPV-18 cervical infection (combined endpoint) in HPV DNA negative subjects at baseline and regardless of initial serostatus, using conditional exact method, at the Month 48 time point (ATP cohort for efficacy) P-value (Per100) HPV-16/18 HPV < Control HPV-16 HPV < Control

7 P-value (Per100) HPV-18 HPV Control For single type: Subjects DNA negative for the corresponding HPV type at Month 0 and Month 6 For combined types: Subjects DNA negative for at least one HPV type at Month 0 and Month 6 (subjects are in the analysis of at least one single type) Subjects with an event were DNA negative for the corresponding HPV type at Month 0 and Month 6 Follow-up period started at day after Dose 3 LL,UL=97.7% Lower and Upper confidence limits P-value=Two-sided Fisher Exact test Primary Efficacy Results: Incidence rates and vaccine efficacy against persistent infection (6-month definition) with HPV-16 and/or HPV-18 (by PCR) and/or CIN1+ associated with HPV-16 and/or HPV-18 cervical infection detected using the HPV TAA (combined endpoint) in HPV DNA negative and seronegative subjects at baseline, using conditional exact method, at the Month 48 time point (ATP cohort for efficacy) P-value (Per100) HPV-16/18 HPV < Control HPV-16 HPV < Control HPV-18 HPV Control For single type: Subjects DNA negative at Month 0 and Month 6 and seronegative at Month 0 for the corresponding HPV type For combined types: Subjects DNA negative at Month 0 and Month 6 and seronegative at Month 0 for at least one HPV type (subjects were in the analysis of at least one single type) Subjects with an event are DNA negative at Month 0 and Month 6 and seronegative at Month 0 for the corresponding HPV type TAA: Type assignment algorithm. The lesion was assigned to an HPV type found in the lesion if a) the same HPV type was found in at least one of the two (closest) preceding cytology samples, or b) none of the HPV types found in the lesion were found in any of the two preceding cytology samples (isolate HPV types) Follow-up period started at day after Dose 3 LL,UL=97.7% Lower and Upper confidence limits P-value=Two-sided Fisher Exact test Primary Efficacy Results: Incidence rates and vaccine efficacy against persistent infection (6-month definition) with HPV-16 and/or HPV-18 (by PCR) and/or CIN1+ associated with HPV-16 and/or HPV-18 cervical infection detected using the HPV TAA (combined endpoint) in HPV DNA negative and seropositive subjects at baseline, using conditional exact method, at the Month 48 time point (ATP cohort for efficacy) P-value HPV-16/18 HPV Control HPV-16 HPV Control

8 P-value HPV-18 HPV Control For single type: Subjects DNA negative at Month 0 and Month 6 and seropositive at Month 0 for the corresponding HPV type For combined types: Subjects DNA negative at Month 0 and Month 6 and seropositive at Month 0 for at least one HPV type (subjects were in the analysis of at least one single type) Subjects with an event are DNA negative at Month 0 and Month 6 and seropositive at Month 0 for the corresponding HPV type TAA: Type assignment algorithm. The lesion was assigned to an HPV type found in the lesion if a) the same HPV type was found in at least one of the two (closest) preceding cytology samples, or b) none of the HPV types found in the lesion were found in any of the two preceding cytology samples (isolate HPV types) Follow-up period started at day after Dose 3 LL,UL=97.7% Lower and Upper confidence limits P-value=Two-sided Fisher Exact test Primary Efficacy Results: Incidence rates and vaccine efficacy against persistent infection (6-month definition) with HPV-16 and/or HPV-18 (by PCR) and/or CIN1+ associated with HPV-16 and/or HPV-18 cervical infection detected using the HPV TAA (combined endpoint) in HPV DNA negative subjects at baseline and regardless of initial serostatus, using conditional exact method, at the Month 48 time point (ATP cohort for efficacy) P-value (Per100) HPV-16/18 HPV < Control HPV-16 HPV < Control HPV-18 HPV Control For single type: Subjects DNA negative for the corresponding HPV type at Month 0 and Month 6 For combined types: Subjects DNA negative for at least one HPV type at Month 0 and Month 6 (subjects were in the analysis of at least one single type) Subjects with an event are DNA negative for the corresponding HPV type at Month 0 and Month 6 TAA: Type assignment algorithm. The lesion was assigned to an HPV type found in the lesion if a) the same HPV type was found in at least one of the two (closest) preceding cytology samples, or b) none of the HPV types found in the lesion were found in any of the two preceding cytology samples (isolate HPV types) Follow-up period started at day after Dose 3 LL,UL=97.7% Lower and Upper confidence limits P-value=Two-sided Fisher Exact test Primary Efficacy Results: Incidence rates and vaccine efficacy against persistent infection (6-month definition) with HPV- 16 and/or HPV-18 (by PCR) and/or CIN1+ associated with HPV-16 and/or HPV-18 cervical infection (combined endpoint) in HPV DNA negative and seronegative subjects at baseline, using conditional exact method, at the Month 84 time point (ATP cohort for efficacy) P-value HPV-16/18 HPV < Control

9 HPV-16 HPV < Control HPV-18 HPV Control For single type: Subjects DNA negative at Month 0 and Month 6 and seronegative at Month 0 for the corresponding HPV type For combined types: Subjects DNA negative at Month 0 and Month 6 and seronegative at Month 0 for at least one HPV type (subjects are in the analysis of at least one single type) Subjects with an event are DNA negative at Month 0 and Month 6 and seronegative at Month 0 for the corresponding HPV type Follow-up period starts at day after Dose 3 LL,UL=96.2% Lower and Upper confidence limits P-value=Two-sided Fisher Exact test Primary Efficacy Results: Incidence rates and vaccine efficacy against persistent infection (6-month definition) with HPV- 16 and/or HPV-18 (by PCR) and/or CIN1+ associated with HPV-16 and/or HPV-18 cervical infection (combined endpoint) in HPV DNA negative and seropositive subjects at baseline, using conditional exact method, at the Month 84 time point (ATP cohort for efficacy) P-value HPV-16/18 HPV Control HPV-16 HPV Control HPV-18 HPV Control For single type: Subjects DNA negative at Month 0 and Month 6 and seropositive at Month 0 for the corresponding HPV type For combined types: Subjects DNA negative at Month 0 and Month 6 and seropositive at Month 0 for at least one HPV type (subjects are in the analysis of at least one single type) Subjects with an event are DNA negative at Month 0 and Month 6 and seropositive at Month 0 for the corresponding HPV type Follow-up period starts at day after Dose 3 LL,UL=96.2% Lower and Upper confidence limits P-value=Two-sided Fisher Exact test Primary Efficacy Results: Incidence rates and vaccine efficacy against persistent infection (6-month definition) with HPV- 16 and/or HPV-18 (by PCR) and/or CIN1+ associated with HPV-16 and/or HPV-18 cervical infection (combined endpoint) in HPV DNA negative subjects at baseline, using conditional exact method, at the Month 84 time point (ATP cohort for efficacy) P-value HPV-16/18 HPV < Control HPV-16 HPV < Control HPV-18 HPV < Control For single type: Subjects DNA negative for the corresponding HPV type at Month 0 and Month 6

10 For combined types: Subjects DNA negative for at least one HPV type at Month 0 and Month 6 (subjects are in the analysis of at least one single type) Subjects with an event are DNA negative for the corresponding HPV type at Month 0 and Month 6 Follow-up period starts at day after Dose 3 LL,UL=96.2% Lower and Upper confidence limits P-value=Two-sided Fisher Exact test Primary Efficacy Results: Incidence rates and vaccine efficacy against persistent infection (6-month definition) with HPV- 16 and/or HPV-18 (by PCR) and/or CIN1+ associated with HPV-16 and/or HPV-18 cervical infection detected using the HPV TAA (combined endpoint) in HPV DNA negative and seronegative subjects at baseline, using conditional exact method, at the Month 84 time point (ATP cohort for efficacy) P-value HPV-16/18 HPV < Control HPV-16 HPV < Control HPV-18 HPV < Control For single type: Subjects DNA negative at Month 0 and Month 6 and seronegative at Month 0 for the corresponding HPV type For combined types: Subjects DNA negative at Month 0 and Month 6 and seronegative at Month 0 for at least one HPV type (subjects are in the analysis of at least one single type) Subjects with an event are DNA negative at Month 0 and Month 6 and seronegative at Month 0 for the corresponding HPV type TAA: Type assignment algorithm. The lesion is assigned to an HPV type found in the lesion if a) the same HPV type is found in at least one of the two (closest) preceding cytology samples, or b) none of the HPV types found in the lesion are found in any of the two preceding cytology samples (isolate HPV types) Follow-up period starts at day after Dose 3 LL,UL=96.2% Lower and Upper confidence limits P-value=Two-sided Fisher Exact test Primary Efficacy Results: Incidence rates and vaccine efficacy against persistent infection (6-month definition) with HPV- 16 and/or HPV-18 (by PCR) and/or CIN1+ associated with HPV-16 and/or HPV-18 cervical infection detected using the HPV TAA (combined endpoint) in HPV DNA negative and seropositive subjects at baseline, using conditional exact method, at the Month 84 time point (ATP cohort for efficacy) P-value HPV-16/18 HPV Control HPV-16 HPV Control HPV-18 HPV Control For single type: Subjects DNA negative at Month 0 and Month 6 and seropositive at Month 0 for the corresponding HPV type For combined types: Subjects DNA negative at Month 0 and Month 6 and seropositive at Month 0 for at least one HPV type (subjects are in the analysis of at least one single type)

11 Subjects with an event are DNA negative at Month 0 and Month 6 and seropositive at Month 0 for the corresponding HPV type TAA: Type assignment algorithm. The lesion is assigned to an HPV type found in the lesion if a) the same HPV type is found in at least one of the two (closest) preceding cytology samples, or b) none of the HPV types found in the lesion are found in any of the two preceding cytology samples (isolate HPV types) Follow-up period starts at day after Dose 3 LL,UL=96.2% Lower and Upper confidence limits P-value=Two-sided Fisher Exact test Primary Efficacy Results: Incidence rates and vaccine efficacy against persistent infection (6-month definition) with HPV- 16 and/or HPV-18 (by PCR) and/or CIN1+ associated with HPV-16 and/or HPV-18 cervical infection detected using the HPV TAA (combined endpoint) in HPV DNA negative subjects at baseline, using conditional exact method, at the Month 84 time point (ATP cohort for efficacy) P-value HPV-16/18 HPV < Control HPV-16 HPV < Control HPV-18 HPV < Control For single type: Subjects DNA negative for the corresponding HPV type at Month 0 and Month 6 For combined types: Subjects DNA negative for at least one HPV type at Month 0 and Month 6 (subjects are in the analysis of at least one single type) Subjects with an event are DNA negative for the corresponding HPV type at Month 0 and Month 6 TAA: Type assignment algorithm. The lesion is assigned to an HPV type found in the lesion if a) the same HPV type is found in at least one of the two (closest) preceding cytology samples, or b) none of the HPV types found in the lesion are found in any of the two preceding cytology samples (isolate HPV types) Follow-up period starts at day after Dose 3 LL,UL=96.2% Lower and Upper confidence limits P-value=Two-sided Fisher Exact test Secondary Outcome Variable (s): Incidence rates and vaccine efficacy against persistent infection (6-month definition) with HPV-16 and/or HPV-18 (by PCR) in HPV DNA negative and seronegative subjects at baseline, using conditional exact method, at the Month 48 time point (ATP cohort for efficacy) (Per100) HPV-16/18 HPV Control HPV-16 HPV Control HPV-18 HPV Control Subjects had at least 5 months of follow-up after Month 12 For single type: Subjects DNA negative at Month 0 and Month 6 and seronegative at Month 0 for the corresponding HPV type For combined types: Subjects DNA negative at Month 0 and Month 6 and seronegative at Month 0 for at least one HPV type (subjects were in the analysis of at least one single type) Subjects with an event were DNA negative at Month 0 and Month 6 and seronegative at Month 0 for the corresponding HPV

12 type Follow-up period starts at day after Dose 3 LL,UL=97.7% Lower and Upper confidence limits Secondary Outcome Variable (s): Incidence rates and vaccine efficacy against persistent infection (6-month definition) with HPV-16 and/or HPV-18 (by PCR) in HPV DNA negative and seropositive subjects at baseline, using conditional exact method, at the Month 48 time point (ATP cohort for efficacy) (Per100) HPV-16/18 HPV Control HPV-16 HPV Control HPV-18 HPV Control Subjects had at least 5 months of follow-up after Month 12 For single type: Subjects DNA negative at Month 0 and Month 6 and seropositive at Month 0 for the corresponding HPV type For combined types: Subjects DNA negative at Month 0 and Month 6 and seropositive at Month 0 for at least one HPV type (subjects were in the analysis of at least one single type) Subjects with an event are DNA negative at Month 0 and Month 6 and seropositive at Month 0 for the corresponding HPV type Follow-up period starts at day after Dose 3 LL,UL=97.7% Lower and Upper confidence limits Secondary Outcome Variable (s): Incidence rates and vaccine efficacy against persistent infection (6-month definition) with HPV-16 and/or HPV-18 (by PCR) in HPV DNA negative subjects at baseline and regardless of initial serostatus, using conditional exact method, at the Month 48 time point (ATP cohort for efficacy) (Per100) HPV-16/18 HPV Control HPV-16 HPV Control HPV-18 HPV Control Subjects had at least 5 months of follow-up after Month 12 For single type: Subjects DNA negative for the corresponding HPV type at Month 0 and Month 6 For combined types: Subjects DNA negative for at least one HPV type at Month 0 and Month 6 (subjects were in the analysis of at least one single type) Subjects with an event were DNA negative for the corresponding HPV type at Month 0 and Month 6 Follow-up period started at day after Dose 3 LL,UL=97.7% Lower and Upper confidence limits Secondary Outcome Variable (s): Incidence rates and vaccine efficacy against persistent infection (12-month definition) with HPV-16 and/or HPV-18 (by PCR) in HPV DNA negative and seronegative subjects at baseline, using conditional exact method, at the Month 48 time point (ATP cohort for efficacy)

13 (Per100) HPV-16/18 HPV Control HPV-16 HPV Control HPV-18 HPV Control Subjects had at least 10 months of follow-up after Month 12 For single type: Subjects DNA negative at Month 0 and Month 6 and seronegative at Month 0 for the corresponding HPV type For combined types: Subjects DNA negative at Month 0 and Month 6 and seronegative at Month 0 for at least one HPV type (subjects were in the analysis of at least one single type) Subjects with an event were DNA negative at Month 0 and Month 6 and seronegative at Month 0 for the corresponding HPV type Follow-up period started at day after Dose 3 LL,UL=97.7% Lower and Upper confidence limits Secondary Outcome Variable (s): Incidence rates and vaccine efficacy against persistent infection (12-month definition) with HPV-16 and/or HPV-18 (by PCR) in HPV DNA negative and seropositive subjects at baseline, using conditional exact method, at the Month 48 time point (ATP cohort for efficacy) HPV-16/18 HPV Control HPV-16 HPV Control HPV-18 HPV Control Subjects had at least 10 months of follow-up after Month 12 For single type: Subjects DNA negative at Month 0 and Month 6 and seropositive at Month 0 for the corresponding HPV type For combined types: Subjects DNA negative at Month 0 and Month 6 and seropositive at Month 0 for at least one HPV type (subjects were in the analysis of at least one single type) Subjects with an event are DNA negative at Month 0 and Month 6 and seropositive at Month 0 for the corresponding HPV type Follow-up period started at day after Dose 3 LL,UL=97.7% Lower and Upper confidence limits Secondary Outcome Variable (s): Incidence rates and vaccine efficacy against persistent infection (12-month definition) with HPV-16 and/or HPV-18 (by PCR) in HPV DNA negative subjects at baseline and regardless of initial serostatus, using conditional exact method, at the Month 48 time point (ATP cohort for efficacy) (Per100) HPV-16/18 HPV Control HPV-16 HPV Control HPV-18 HPV

14 (Per100) Control Subjects had at least 10 months of follow-up after Month 12 For single type: Subjects DNA negative for the corresponding HPV type at Month 0 and Month 6 For combined types: Subjects DNA negative for at least one HPV type at Month 0 and Month 6 (subjects were in the analysis of at least one single type) Subjects with an event are DNA negative for the corresponding HPV type at Month 0 and Month 6 Follow-up period started at day after Dose 3 LL,UL=97.7% Lower and Upper confidence limits Secondary Outcome Variable (s): Incidence rates and vaccine efficacy against persistent infection (6-month definition) with oncogenic HPV types individually or in combination, in HPV DNA negative subjects at baseline and regardless of initial serostatus, using conditional exact method, at the Month 48 time point (ATP cohort for efficacy) (Per100) HPV-16 HPV Control HPV-18 HPV Control HPV-31 HPV Control HPV-33 HPV Control HPV-35 HPV Control HPV-39 HPV Control HPV-45 HPV Control HPV-51 HPV Control HPV-52 HPV Control HPV-56 HPV Control HPV-58 HPV Control HPV-59 HPV Control HPV-66 HPV Control HPV-68 HPV Control HPV-31/45 HPV Control HPV-31/45/33/52/58 HPV Control HPV-39/45/59/68 HPV Control

15 HPV-31/33/35/52/58 HPV Control HPV-31/45/33/52/58/35/39/51/56/59 HPV Control HPV-HRW HPV Control HPV-HR HPV Control Subjects had at least 5 months of follow-up after Month 12 For single type: Subjects DNA negative for the corresponding HPV type at Month 0 and Month 6 For combined types: Subjects DNA negative for at least one HPV type at Month 0 and Month 6 (subjects were in the analysis of at least one single type) Subjects with an event were DNA negative for the corresponding HPV type at Month 0 and Month 6 HPV-HRW = All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18 HPV-HR = High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68 Follow-up period started at day after Dose 3 LL,UL=97.7% Lower and Upper confidence limits Secondary Outcome Variable (s): Incidence rates and vaccine efficacy against persistent infection (12-month definition) with oncogenic HPV types individually or in combination, in HPV DNA negative subjects at baseline and regardless of initial serostatus, using conditional exact method, at the Month 48 time point (ATP cohort for efficacy) (Per100) HPV-16 HPV Control HPV-18 HPV Control HPV-31 HPV Control HPV-33 HPV Control HPV-35 HPV Control HPV-39 HPV Control HPV-45 HPV Control HPV-51 HPV Control HPV-52 HPV Control HPV-56 HPV Control HPV-58 HPV Control HPV-59 HPV Control HPV-66 HPV Control HPV-68 HPV Control

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: he study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Analysis of immunogenicity

Analysis of immunogenicity The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

subjects having anti-hav antibody concentrations 100 miu/ml at the pre- additional vaccination time point.

subjects having anti-hav antibody concentrations 100 miu/ml at the pre- additional vaccination time point. The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

For the additional vaccination phase

For the additional vaccination phase The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Long-term follow-up at Month 198: 21 October 2008 to 07 December Long-term follow-up at Month 186: 01 October 2007 to 19 December 2008

Long-term follow-up at Month 198: 21 October 2008 to 07 December Long-term follow-up at Month 186: 01 October 2007 to 19 December 2008 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:

Study No.: Title: Rationale:  Phase: Study Period: Study Design: Centres: Indication: Treatment: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

HBV-2 Group: neonates born to HBsAg+ and HBeAg+ mothers who received a 4-dose vaccination regimen (Part of

HBV-2 Group: neonates born to HBsAg+ and HBeAg+ mothers who received a 4-dose vaccination regimen (Part of The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

To demonstrate that DTPa-HBV-IPV/Hib-MenC-TT co-administered with 10Pn, is non-inferior to DTPa-HBV-IPV/Hib coadministered

To demonstrate that DTPa-HBV-IPV/Hib-MenC-TT co-administered with 10Pn, is non-inferior to DTPa-HBV-IPV/Hib coadministered The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

MenC. MenW MenY

MenC. MenW MenY The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Update on Clinical Trials for Bivalent HPV Vaccine

Update on Clinical Trials for Bivalent HPV Vaccine Update on Clinical Trials for Bivalent HPV Vaccine A/Prof Quek Swee Chong Medical Director Parkway Gynaecology Screening & Treatment Centre Gleneagles Hospital, Singapore Disclosure of interest Swee Chong

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable(s):

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable(s): The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

vaccination. Children enrolled in these clusters between 6 weeks and 6 months of age received a 2-dose primary vaccination schedule.

vaccination. Children enrolled in these clusters between 6 weeks and 6 months of age received a 2-dose primary vaccination schedule. The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Synopsis of study HBV-314 BST 280 (108988)

Synopsis of study HBV-314 BST 280 (108988) Synopsis of study HBV-314 BST 280 (108988) Pharmaceutical entrepreneur: GlaxoSmithKline GmbH & Co. KG Prinzregentenplatz 9 81675 Munich Germany Personal identifiable data of investigators (name / full

More information

CERVARIX PRODUCT INFORMATION Human Papillomavirus Vaccine Types 16 and 18 (Recombinant, AS04 adjuvanted)

CERVARIX PRODUCT INFORMATION Human Papillomavirus Vaccine Types 16 and 18 (Recombinant, AS04 adjuvanted) CERVARIX PRODUCT INFORMATION Human Papillomavirus Vaccine Types 16 and 18 (Recombinant, AS04 adjuvanted) DESCRIPTION CERVARIX contains recombinant C-terminally truncated L1 proteins from human papillomavirus

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Periods: Study Design: Centers: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Periods: Study Design: Centers: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Note: Phase: Study Period: Study Design: Centres: Indication: Treatment: Hib-MenCY F1 Group Hib-MenCY F2 Group

Study No.: Title: Rationale: Note: Phase: Study Period: Study Design: Centres: Indication: Treatment: Hib-MenCY F1 Group Hib-MenCY F2 Group The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

CERVARIX PRODUCT INFORMATION Human Papillomavirus Vaccine Types 16 and 18 (Recombinant, AS04 adjuvanted)

CERVARIX PRODUCT INFORMATION Human Papillomavirus Vaccine Types 16 and 18 (Recombinant, AS04 adjuvanted) CERVARIX PRODUCT INFORMATION Human Papillomavirus Vaccine Types 16 and 18 (Recombinant, AS04 adjuvanted) DESCRIPTION CERVARIX contains recombinant C-terminally truncated L1 proteins from human papillomavirus

More information

Synopsis for study HAV-112 EXT M210 (110678)

Synopsis for study HAV-112 EXT M210 (110678) Synopsis for study HAV-112 EXT M210 (110678) Pharmaceutical entrepreneur: GlaxoSmithKline GmbH & Co. KG Prinzregentenplatz 9 81675 Munich Germany Personal identifiable data of investigators (name / full

More information

AUSTRALIAN PRODUCT INFORMATION. CERVARIX human papillomavirus vaccine types 16 and 18 (recombinant, AS04 adjuvanted) suspension for injection

AUSTRALIAN PRODUCT INFORMATION. CERVARIX human papillomavirus vaccine types 16 and 18 (recombinant, AS04 adjuvanted) suspension for injection AUSTRALIAN PRODUCT INFORMATION CERVARIX human papillomavirus vaccine types 16 and 18 (recombinant, AS04 adjuvanted) suspension for injection 1 NAME OF THE MEDICINE Human Papillomavirus Vaccine Types 16

More information

D-QIV_LP 6-35m Group: Subjects aged 6-35 months received 1 or 2 doses of D-QIV_IP vaccine depending on vaccine-priming

D-QIV_LP 6-35m Group: Subjects aged 6-35 months received 1 or 2 doses of D-QIV_IP vaccine depending on vaccine-priming The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

CERVARIX [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant] Suspension for Intramuscular Injection Initial U.S.

CERVARIX [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant] Suspension for Intramuscular Injection Initial U.S. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CERVARIX safely and effectively. See full prescribing information for CERVARIX. CERVARIX [Human Papillomavirus

More information

Analysis of safety The analysis was performed on the Total Vaccinated cohort.

Analysis of safety The analysis was performed on the Total Vaccinated cohort. The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

See 17 for PATIENT COUNSELING INFORMATION. Revised: Month Year

See 17 for PATIENT COUNSELING INFORMATION. Revised: Month Year HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CERVARIX safely and effectively. See full prescribing information for CERVARIX. CERVARIX [Human Papillomavirus

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variables:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variables: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

See 17 for PATIENT COUNSELING INFORMATION and FDAapproved. Revised: 08/2012

See 17 for PATIENT COUNSELING INFORMATION and FDAapproved. Revised: 08/2012 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CERVARIX safely and effectively. See full prescribing information for CERVARIX. CERVARIX [Human Papillomavirus

More information

See 17 for PATIENT COUNSELING INFORMATION and FDAapproved. Revised: xx/xxxx

See 17 for PATIENT COUNSELING INFORMATION and FDAapproved. Revised: xx/xxxx HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CERVARIX safely and effectively. See full prescribing information for CERVARIX. CERVARIX [Human Papillomavirus

More information

See 17 for PATIENT COUNSELING INFORMATION and FDAapproved. Revised: XX/XXXX

See 17 for PATIENT COUNSELING INFORMATION and FDAapproved. Revised: XX/XXXX HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CERVARIX safely and effectively. See full prescribing information for CERVARIX. CERVARIX [Human Papillomavirus

More information

CERVARIX GlaxoSmithKline

CERVARIX GlaxoSmithKline CERVARIX GlaxoSmithKline International Data Sheet. Version 2 (31/01/2007) Cervarix 1. Name of the medicinal product CervarixTM Human Papillomavirus vaccine Types 16 and 18 (Recombinant, AS04 adjuvanted).

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Study vaccines Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Study vaccines Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Cervical Cancer Vaccine:

GSK Cervical Cancer Vaccine: GSK Cervical Cancer Vaccine: Overview of Clinical Data Jovelle B. Laoag-Fernandez, M.D., Ph.D., FPOGS Regional Medical Affairs HPV Vaccines GSK Biologicals Asia Pacific, Australasia, China/Hong Kong, Japan

More information

The promise of HPV vaccines for Cervical (and other genital cancer) prevention

The promise of HPV vaccines for Cervical (and other genital cancer) prevention The promise of HPV vaccines for Cervical (and other genital cancer) prevention CONTROVERSIES IN OBSTETRICS GYNECOLOGY & INFERTILITY Barcelona March 27 F. Xavier Bosch Catalan Institute of Oncology CURRENT

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

PDF of Trial CTRI Website URL -

PDF of Trial CTRI Website URL - Clinical Trial Details (PDF Generation Date :- Wed, 27 Mar 2019 20:50:17 GMT) CTRI Number CTRI/2009/091/001039 [Registered on: 15/10/2010] - Last Modified On 11/06/2015 Post Graduate Thesis Type of Trial

More information

- Infanrix hexa (DTPa-HBV-IPV/Hib): GSK Biologicals combined diphtheria, tetanus, acellular pertussis, hepatitis

- Infanrix hexa (DTPa-HBV-IPV/Hib): GSK Biologicals combined diphtheria, tetanus, acellular pertussis, hepatitis The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

HPV 31 (79 1%, 97 7% CI

HPV 31 (79 1%, 97 7% CI Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Woo Dae Kang, Ho Sun Choi, Seok Mo Kim

Woo Dae Kang, Ho Sun Choi, Seok Mo Kim Is vaccination with quadrivalent HPV vaccine after Loop Electrosurgical Excision Procedure effective in preventing recurrence in patients with High-grade Cervical Intraepithelial Neoplasia (CIN2-3)? Chonnam

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Cervarix suspension for injection Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed) 2. QUALITATIVE

More information

CERVARIX PRODUCT INFORMATION Human Papillomavirus Vaccine Types 16 and 18 (Recombinant, AS04 adjuvanted)

CERVARIX PRODUCT INFORMATION Human Papillomavirus Vaccine Types 16 and 18 (Recombinant, AS04 adjuvanted) CERVARIX PRODUCT INFORMATION Human Papillomavirus Vaccine Types 16 and 18 (Recombinant, AS04 adjuvanted) DESCRIPTION CERVARIX contains recombinant C-terminally truncated L1 proteins from human papillomavirus

More information

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory CERVARIX. Human Papillomavirus Vaccine rdna Ph Eur

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory CERVARIX. Human Papillomavirus Vaccine rdna Ph Eur For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory CERVARIX Human Papillomavirus Vaccine rdna Ph Eur 1. NAME OF THE MEDICINAL PRODUCT Human Papillomavirus Vaccine rdna

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

PRODUCT INFORMATION GARDASIL 9. [Human Papillomavirus 9-valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) vaccine, Recombinant]

PRODUCT INFORMATION GARDASIL 9. [Human Papillomavirus 9-valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) vaccine, Recombinant] PRODUCT INFORMATION GARDASIL 9 [Human Papillomavirus 9-valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) vaccine, Recombinant] DESCRIPTION GARDASIL 9 *, Human Papillomavirus 9-valent Vaccine, Recombinant,

More information

Prophylactic HPV Vaccines. Margaret Stanley Department of Pathology Cambridge

Prophylactic HPV Vaccines. Margaret Stanley Department of Pathology Cambridge Prophylactic HPV Vaccines Margaret Stanley Department of Pathology Cambridge 8kb double stranded DNA viruses, absolutely host and tissue specific, Can t grow virus in tissue culture Classified by genotype

More information

Clinical overview of GSK s AS04 adjuvanted vaccine: data up to 6.4 years

Clinical overview of GSK s AS04 adjuvanted vaccine: data up to 6.4 years Clinical overview of GSK s AS04 adjuvanted vaccine: data up to 6.4 years Gudrun Maechler Director, Clinical & Medical Affairs Europe & Cervarix GSK Biologicals Presentation Outline HPV immunology Immunogenicity

More information

Largest efficacy trial of a cervical cancer vaccine showed Cervarix protects against the five most common cancercausing

Largest efficacy trial of a cervical cancer vaccine showed Cervarix protects against the five most common cancercausing FOR IMMEDIATE RELEASE Largest efficacy trial of a cervical cancer vaccine showed Cervarix protects against the five most common cancercausing virus types Published in The Lancet: Additional efficacy could

More information

Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines

Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Tim Kremer, MD Ralph Anderson, MD 1 Objectives Describe the natural history of HPV particularly as it relates

More information

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory CERVARIX. Human Papillomavirus Vaccine rdna Ph Eur

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory CERVARIX. Human Papillomavirus Vaccine rdna Ph Eur For the use only of Registered Medical Practitioners or a Hospital or a Laboratory CERVARIX Human Papillomavirus Vaccine rdna Ph Eur 1. NAME OF THE MEDICINAL PRODUCT Human Papillomavirus Vaccine rdna Ph

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Cervarix suspension for injection in pre-filled syringe Cervarix suspension for injection in a vial Cervarix suspension for

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Cervarix suspension for injection Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed) 2. QUALITATIVE

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Cervarix suspension for injection Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed) 2. QUALITATIVE

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

I have no financial interests in any product I will discuss today.

I have no financial interests in any product I will discuss today. Cervical Cancer Prevention: 2012 and Beyond George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics University of California,

More information

SCCPS Scientific Committee Position Paper on HPV Vaccination

SCCPS Scientific Committee Position Paper on HPV Vaccination SCCPS Scientific Committee Position Paper on HPV Vaccination Adapted from Joint Statement (March 2011) of the: Obstetrical & Gynaecological Society of Singapore (OGSS) Society for Colposcopy and Cervical

More information

SYNOPSIS. Clinical Study Report IM Double-blind Period

SYNOPSIS. Clinical Study Report IM Double-blind Period Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier SYNOPSIS (For National Authority

More information

Understanding Your Pap Test Results

Understanding Your Pap Test Results Understanding Your Pap Test Results Most laboratories in the United States use a standard set of terms called the Bethesda System to report pap test results. Normal: Pap samples that have no cell abnormalities

More information

GSK Medicine: Study Number:

GSK Medicine: Study Number: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Eradicating Mortality from Cervical Cancer

Eradicating Mortality from Cervical Cancer Eradicating Mortality from Cervical Cancer Michelle Berlin, MD, MPH Vice Chair, Obstetrics & Gynecology Associate Director, Center for Women s Health June 2, 2009 Overview Prevention Human Papilloma Virus

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

An update on the Human Papillomavirus Vaccines. I have no financial conflicts of interest. Case 1. Objectives 10/26/2016

An update on the Human Papillomavirus Vaccines. I have no financial conflicts of interest. Case 1. Objectives 10/26/2016 An update on the Human Papillomavirus Vaccines Karen Smith-McCune Professor, UCSF Department of Obstetrics, Gynecology and Reproductive Sciences John Kerner Endowed Chair I have no financial conflicts

More information

ABC/3TC/ZDV ABC PBO/3TC/ZDV

ABC/3TC/ZDV ABC PBO/3TC/ZDV The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two

Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two Seshu P. Sarma, MD, FAAP Emory University Regional Training Center Atlanta, Georgia Produced by the Alabama Department of Public Health

More information

Focus. A case. I have no conflicts of interest. HPV Vaccination: Science and Practice. Collaborative effort with Karen Smith-McCune, MD, PhD 2/19/2010

Focus. A case. I have no conflicts of interest. HPV Vaccination: Science and Practice. Collaborative effort with Karen Smith-McCune, MD, PhD 2/19/2010 HPV Vaccination: Science and Practice George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics Director, Colposcopy Clinic,

More information

!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$

!#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$ !"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$ Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology

More information

Following microtrauma, HPV s bind to the basement membrane, infect basal cells, and replicate in suprabasal cells

Following microtrauma, HPV s bind to the basement membrane, infect basal cells, and replicate in suprabasal cells Following microtrauma, HPV s bind to the basement membrane, infect basal cells, and replicate in suprabasal cells Virion Assembled Virus Stratified squamous epithelium Virion Suprabasal cells HPV DNA replication

More information

Making Sense of Cervical Cancer Screening

Making Sense of Cervical Cancer Screening Making Sense of Cervical Cancer Screening New Guidelines published November 2012 Tammie Koehler DO, FACOG The incidence of cervical cancer in the US has decreased more than 50% in the past 30 years because

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information